Pharmaceutical packaging has an increasing importance in aging societies, where
people depend on medicines for their own care and well-being. Previous research shows that pharmaceutical packaging is a source of uncertainties, confusion, and daily struggles. The challenges experienced by users are extensive; the pharmaceutical industry needs to respond with packaging innovation. To address these complex challenges, more research is necessary on packaging that fulfills user needs and capabilities. This research purpose is to investigate innovation and design processes for pharmaceutical packaging, as well as to stimulate the uptake of inclusive design toward pharmaceutical packaging that meets society’s needs.
Although statin therapy has proven to be the cornerstone for prevention and treatment of cardiovascular disease (CVD), there are many patients for whom long-term therapy remains suboptimal. The aims of this article are to review the current complex issues associated with statin use and to explore when novel treatment approaches should be considered.
Statin discontinuation as well as adherence to statin therapy remain two of the greatest challenges for lipidologists. Evidence suggests that between 40 and 75% of patients discontinue their statin therapy within one year after initiation. Furthermore, whilst the reasons for persistence with statin therapy are complex, evidence shows that low-adherence to statins negatively impacts clinical outcomes and residual CV risk remains a major concern.
Non-adherence or lack of persistence with long-term statin therapy in real-life may be the main cause of inadequate low density lipoprotein cholesterol lowering with statins. There is a large need for the improvement of the use of statins, which have good safety profiles and are inexpensive. On the other hand, in a non-cost-constrained environment, proprotein convertase subtilisin/kexin type 9 inhibitors should arguably be used more often in those patients in whom treatment with statins remains unsatisfactory.